The primary objective of this open-label extension trial was to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 or ACCORD-2.
This was a multi-center, open-label extension trial to evaluate the long-term safety of AXS-05 in subjects with Alzheimer's disease (AD) agitation that continued to receive AXS-05 given completion of ADVANCE-2 (AXS-05-AD-304) or ACCORD-2 (AXS-05-AD-303).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
139
AXS-05 tablets, taken twice daily
Clinical Research Site
Peoria, Arizona, United States
Long-Term Safety
Incidence of treatment-emergent adverse events following dosing with AXS-05
Time frame: Up to 25 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Research Site
Walnut Creek, California, United States
Clinical Research Site
Bonita Springs, Florida, United States
Clinical Research Site
Brandon, Florida, United States
Clinical Research Site
Greenacres City, Florida, United States
Clinical Research Site
Hialeah, Florida, United States
Clinical Research Site
Miami, Florida, United States
Clinical Research Site
Miami, Florida, United States
Clinical Research Site
Miami, Florida, United States
Clinical Research Site
Miami, Florida, United States
...and 12 more locations